CTMX - CIK 0001501989
The table below shows CytomX Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$75.59M | -$86.23M | -$56.03M | -$110.79M | -$119.03M | $5.26M |
| Capital expenditure | $220.00K | $310.00K | $840.00K | $1.74M | $1.61M | $2.31M |
| Investing cash flow | -$59.74M | $99.70M | -$150.67M | $98.26M | $22.49M | -$18.72M |
| Dividends paid | - | - | - | - | - |
CytomX Therapeutics, Inc. reported operating cash flow of -$75.59M for fiscal year 2025. That is up 12.3% from -$86.23M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$2.03M (FY 2016) to -$75.59M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $110.45M | $7.52M | $30.23M | $648.00K | $110.21M | $16.89M |